Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Drug Industry Boosts Lobbying Coffers; Amgen Doubles Its Expenditures

Executive Summary

Lobbyists for the pharmaceutical industry have had plenty of work this year as Congress pushed forward legislation to overhaul the patent system, mandate lower drug prices for Medicare, and clear the way for approval of generic biologics

You may also be interested in...

Patent Reform Bill Clears House; BIO Opposes Provision on Damages Awards

A House patent reform provision on apportionment of damages in infringement suits is likely to be revised, despite House passage of the legislation Sept. 7 by a vote of 220-175

Comparative Effectiveness, Generic Biologics Draw Insurers’ Lobbying Efforts

Comparative effectiveness research and generic biologics are among the key pharmaceutical issues that attracted lobbying efforts by large health insurers in the first half of 2007, according to reports filed recently with Congress

Aranesp Bad Luck Catches Up To Amgen, Forces Pharma-Style Reorganization

As Amgen enters into a major restructuring effort that will include extensive cost-cutting and significant headcount reductions, it will also make serious adjustments to its R&D program - including scaling back from its industry-leading approach of investing a high percentage of sales on R&D

Related Content

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts